Theme |
Evidence-based strategies for secondary hyperparathyroidism |
Title |
New predictable marker; FGF-23 for the stage of secondary hyperparathyroidism |
Author |
Shohei Nakanishi |
The Nephrology Center, Toranomon Hospital |
Author |
Masafumi Fukagawa |
Division of Nephrology and Dialysis Center, Kobe University School of Medicine |
[ Summary ] |
It is important to choose the most suitable therapies for the stage of secondary hyperparathyroidism. FGF-23 was discoverd through analysis of hereditary diseases with hypophosphatemia and it is thought that FGF-23 is one of phosphatonin. It is possible to predict the prognosis for secondary hyperparathyroidism by serum FGF-23 levels. |